MAPT and Alzheimer disease: As evidenced from recent PET imaging studies and meta-analyses of published biomarker data, a strong association between total tau levels in both cerebrospinal fluid and blood with cognitive impairment in AD patients has been detected (Hampel et al., 2018; Wattmo et al., 2020).